TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05895851

Intervention type: RADIATION
Intervention: head and neck radiation
Description: RON and non-RON: nasopharyngeal carcinoma patients recieved head and neck radiation; Normal: normal individuals.

Intervention type: RADIATION
Intervention: head and neck radiation
Description: RON and non-RON: nasopharyngeal carcinoma patients recieved head and neck radiation; Normal: normal individuals.
Study: NCT00576914

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human endostatin
Description: recombinant human endostatin 15mg per ampul for injection 7.5mg/m2 IV (in the vein) on 1st to 14th days of a 21- day cycle, totally 4 cycles are needed
Study: NCT02284867

Intervention type: OTHER
Intervention: immunohistochemistry study
Description: After taking informed written consent,a placental sample will be taken either the patient delivered preterm or at term (term patients will be either control term group or patients with successful treatment of preterm labor). The placental sample taken should have part of the decidua and then the sample will be fixed in 10% neutral-buffered formalin for 24-48 h, routinely processed, embedded in paraffin wax, sectioned at 3 μm thickness, and mounted on 3-aminopropyl-triethoxysilane -coated slides. Serial sections will be immunostained for CD 16 and CD56 . immunohistochemistry study will be done at Ain Shams Maternity Hospital Histopathology department.
Study: NCT00576914

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: recombinant human endostatin
Description: recombinant human endostatin 15mg per ampul for injection 7.5mg/m2 IV (in the vein) on 1st to 14th days of a 21- day cycle, totally 4 cycles are needed
Study: NCT02739412

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Subjects will self-administer low dose IL-2 as subQ injection (0.30 MIU per meter squared body surface area) for 4 weeks.
Study: NCT02928640

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClariCore System
Description: Data collection to build the prostrate tissue classification algorithm.
Study: NCT03270787

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo Placebo,10pills,tid,treat 1 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound danshen dripping pills
Description: Drug: Compound danshen dripping pills Compound danshen dripping pills,10pills,tid,treat 1 weeks.
Study: NCT04121910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: On Study Day 1 and Study Day 18, savolitinib will be administered as single dose after a high-fat, high-calorie breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Twice daily on first day of dosing (Study Day 15) followed by once daily for 4 days (Study Day 16 - Study Day 19) administered 1 hour before any breakfast (and 1 hour before dinner on Study Day 15)
Study: NCT01893177

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inflexal V
Description: Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL Inflexal V

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inflexal V
Description: Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL Inflexal V
Study: NCT01738035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEFECON
Description: All patients will receive a maximum recommended daily dose of an ACEI and/or ARB (or maximum tolerated dose not exceeding the maximum recommended daily dose) for the duration of the treatment and follow-up phases.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEFECON
Description: All patients will receive a maximum recommended daily dose of an ACEI and/or ARB (or maximum tolerated dose not exceeding the maximum recommended daily dose) for the duration of the treatment and follow-up phases.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients will receive a maximum recommended daily dose of an ACEI and/or ARB (or maximum tolerated dose not exceeding the maximum recommended daily dose) for the duration of the treatment and follow-up phases.
Study: NCT02417623

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone Application group
Description: Intervention group will receive a 12-month weight loss programmed that implements recommendations of a Clinical Practice Guideline, complemented with a smartphone app
Study: NCT04507750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Carmelizumab: Intravenous infusion of a fixed dose of 200 mg in 30 minutes (not less than 20 minutes, not more than 60 minutes), once every 3 weeks, continuous administration until the disease progresses, the patient If death or intolerable toxicity occurs, medication for up to 1 year; Apatinib mesylate tablets: The initial dose is 250 mg, administered once a day, and continue to be administered. If there is a grade 3 to 4 adverse reaction, it should be administered once every other day.
Study: NCT05295277

Intervention type: OTHER
Intervention: Standard of care genetic testing group
Description: N/A - no intervention as this is an observational study.
Study: NCT00729430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acids (Fish Oil Supplements)
Description: 4 grams of omega-3 fatty acids taken orally once per day for 6 months
Study: NCT02197195

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chocolate Milk

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chocolate Milk

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fruit Drink

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fruit Drink

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study: NCT01770223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PegIFN-2b

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Study: NCT03679091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low-dose ticagrelor
Description: low-dose ticagrelor (60.0 mg once daily) for 7 days,followed by a 2-week washout period then a 7 days crossover phase of clopidogrel (75mg once daily).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose ticagrelor
Description: low-dose ticagrelor (60.0 mg once daily) for 7 days,followed by a 2-week washout period then a 7 days crossover phase of clopidogrel (75mg once daily).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: clopidogrel (75mg once daily) for 7 days,followed by a 2-week washout period then a 7 days crossover phase of low-dose ticagrelor (60.0 mg once daily).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: clopidogrel (75mg once daily) for 7 days,followed by a 2-week washout period then a 7 days crossover phase of low-dose ticagrelor (60.0 mg once daily).
Study: NCT03373643

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: OSA screening
Description: Full night polysomnography
Study: NCT03935815

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine injection
Description: 30 mL of 0.25% ropivacaine will be administered on both the right and left sides with a 20 gauge, 4 inch ultrasound needle using a SonoSite ultrasound machine with a linear transducer probe. The tip of the ultrasound needle will be placed posterior to the quadratus lumborum muscle (QL2) made in the plane between the quadratus lumborum muscle and thoracolumbar fascia.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: A sham procedure with a superficial 22 gauge needle stick will be performed without injectate.
Study: NCT02113566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 1000mg
Description: Subjects who require rescue medication between hours 4 and 6 will be allowed to take Dose 2 of the study medication. If the subject chooses to take a rescue analgesic (acetaminophen 1000mg), they will be considered a treatment failure. This intervention will be use for the placebo and Ibuprofen arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen 1000mg
Description: Subjects who require rescue medication between hours 4 and 6 will be allowed to take Dose 2 of the study medication. If the subject chooses to take a rescue analgesic (acetaminophen 1000mg), they will be considered a treatment failure. This intervention will be use for the placebo and Ibuprofen arm.
Study: NCT02372032

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous lumbar discectomy
Description: process percutaneous lumbar discectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous lumbar discectomy
Description: process percutaneous lumbar discectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ozone therapy
Description: percutaneous intradiscal ozone injection
Study: NCT01232907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Carnitine
Description: L-Carnitine, a pharmaceutical product, for the treatment of fatigue in persons with spinal cord injury will be used for this study. L-Carnitine is a nutrient normally obtained in the fat from meat. It promotes fatty acid oxidation of muscle, thereby promoting efficient energy production. Treatment with L-Carnitine has been shown to produce clinically significant improvement in fatigue in persons with multiple sclerosis (MS), cancer, and in aging populations. While the causes of fatigue in persons with SCI may be multifactorial, successful use of L-Carnitine in MS-related fatigue suggests it may have a role in SCI. Standard treatment will entail daily dosages of 1980 milligrams of L-Carnitine (three 330 mg tablets in the morning and three 330 mg tablets in the evening) for 4 weeks.
Study: NCT03150797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo
Study: NCT03307850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation During Exercise and Stress
Description: Patients with type 1 diabetes (T1D) on an insulin pump will be studied for 5 weeks in the outpatient setting performing their normal activities, to include their normal diet and exercise, while assessing the amount of type of exercise performed, and emotional stress levels, using stress sensor, questionnaires and salivary cortisol levels.~Subjects at the William Sansum Diabetes Center will perform graded exercise on a treadmill for up to 45 minutes with all activity and stress monitors running, achieving 30 and 60% calculated heart rate reserve, once during the study. Subjects at Mayo Clinic will perform a graded exercise test on a treadmill to determine V02max and ensure stable cardiac status, once during the study.
Study: NCT04104542

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based stress reduction
Description: on-line training on the website = www.palousemindfulness.com

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based stress reduction
Description: on-line training on the website = www.palousemindfulness.com

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Healthy Lifestyle
Description: Diet and Exercise

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Healthy Lifestyle
Description: Diet and Exercise
Study: NCT04737135

Intervention type: OTHER
Intervention: Non intervention
Description: Patients without intervention
Study: NCT03484819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib Hydrochloride
Description: Given IV
Study: NCT04537663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacille Calmette-Guérin (BCG)
Description: Participants in the intervention group will be vaccinated with the licensed BCG vaccine (Danish strain 1331, SSI, Denmark) using the standard vaccination technique for this vaccine (intradermal injection in the left upper arm).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal injection of sterile 0.9% NaCl.
Study: NCT00729430

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets taken orally once per day for 6 months
Study: NCT04733755

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beauty Image
Description: 1.97g/package; 2 packages one day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Placebo Control; 1.97g/package; 2 packages one day for 8 weeks
Study: NCT04557345

Intervention type: DIAGNOSTIC_TEST
Intervention: Determination of cytokines
Description: Subsequently, a blood sample will be taken from which the processing will be as follows: 6 ml of peripheral blood will be taken in tubes with a yellow cap and inert gel and clot retractor, immediately afterward it will be placed on ice, it will be transported to the laboratory where it will be centrifuged at 2500 rpm for 15 minutes at 4 degrees centigrade, immediately afterward 500 µl of serum will be aliquoted and stored at minus 75 ° C until later analysis. The general methodology for sandwich ELISA will be used.

Intervention type: DIAGNOSTIC_TEST
Intervention: Determination of cytokines
Description: Subsequently, a blood sample will be taken from which the processing will be as follows: 6 ml of peripheral blood will be taken in tubes with a yellow cap and inert gel and clot retractor, immediately afterward it will be placed on ice, it will be transported to the laboratory where it will be centrifuged at 2500 rpm for 15 minutes at 4 degrees centigrade, immediately afterward 500 µl of serum will be aliquoted and stored at minus 75 ° C until later analysis. The general methodology for sandwich ELISA will be used.

Intervention type: DIAGNOSTIC_TEST
Intervention: Determination of cytokines
Description: Subsequently, a blood sample will be taken from which the processing will be as follows: 6 ml of peripheral blood will be taken in tubes with a yellow cap and inert gel and clot retractor, immediately afterward it will be placed on ice, it will be transported to the laboratory where it will be centrifuged at 2500 rpm for 15 minutes at 4 degrees centigrade, immediately afterward 500 µl of serum will be aliquoted and stored at minus 75 ° C until later analysis. The general methodology for sandwich ELISA will be used.
Study: NCT02987153

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Kypho-IORT
Description: The radiation source is inserted into the lesion and switched on for a few minutes to provide intraoperative radiotherapy accurately targeted to the tissues that are at the highest risk of local recurrence. The dosimetric characteristics and clinical applications of this device have been well studied.
Study: NCT00270634

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voclosporin
Description: voclosporin 0.4, 0.6, 0.8 mg/kg po BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voclosporin
Description: voclosporin 0.4, 0.6, 0.8 mg/kg po BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voclosporin
Description: voclosporin 0.4, 0.6, 0.8 mg/kg po BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: tacrolimus 0.05 mg/kg po BID
Study: NCT06152458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Patients in the intervention group (G1) (n=23) received the combined vitamin therapy: IV vitamin C (1.5 g every 6 hours administered as an infusion over 30 to 60 minutes and mixed in a 100- mL solution of normal saline), hydrocortisone (100 mg in bolus-100 mg in perfusor up to 60 min (200mg 24h),), and thiamine (200 mg every 12 hours administered as an infusion over 30 to 60 minutes and mixed in a 100-mL solution of normal saline) for 3 days.
Study: NCT03461445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envarsus
Description: Patients will be randomized to receiving Envarsus instead of IR Tacrolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IR Tacrolimus
Description: Patients will be randomized to receiving IR Tacrolimus instead of Envarsus
Study: NCT00421304

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Motavizumab
Description: A single IV dose of motavizumab 30 mg/kg or 100 mg/kg will be administered on Day 0 of the study.
Study: NCT03067311

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-CAT
Description: I-CAT is a novel therapeutic intervention combining mindfulness and meditation strategies to improve stress reactivity and increase meaningful coping, as well as a range of possible proximal (e.g. autonomic, endocrine, immune indices of stress reactivity, symptom severity) and distal measures (function, relapse, quality of life).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as usual defined by participant clinician at OASIS clinic.
Study: NCT00421304

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Motavizumab
Description: A single IV dose of motavizumab 30 mg/kg or 100 mg/kg will be administered on Day 0 of the study.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single IV dose of placebo matched to motavizumab will be administered on Day 0 of the study.
Study: NCT01367054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glifage
Description: 500 mg tablet
Study: NCT02476045

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil,leucovorin,panitumumab
Description: Maintenance treatment (ARM A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: Maintenance treatment (ARM B)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin, 5-fluorouracil,leucovorin,panitumumab
Description: Induction treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, 5-fluorouracil,leucovorin,panitumumab
Description: Induction treatment
Study: NCT04823832

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pancreaticoduodenectomy
Description: resection of the head of pancreas and the duodenum followed by triple anastomosis
Study: NCT04557345

Intervention type: DIAGNOSTIC_TEST
Intervention: Determination of cytokines
Description: Subsequently, a blood sample will be taken from which the processing will be as follows: 6 ml of peripheral blood will be taken in tubes with a yellow cap and inert gel and clot retractor, immediately afterward it will be placed on ice, it will be transported to the laboratory where it will be centrifuged at 2500 rpm for 15 minutes at 4 degrees centigrade, immediately afterward 500 µl of serum will be aliquoted and stored at minus 75 ° C until later analysis. The general methodology for sandwich ELISA will be used.
Study: NCT03905980

Intervention type: PROCEDURE
Intervention: vaginal delivery
Description: pregnancy ended by vaginal delivery

Intervention type: PROCEDURE
Intervention: Cesarean section
Description: pregnancy ended by cesarean delivery
Study: NCT00573313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine
Description: Alcoholic liver disease patients received drug at dose of 400 mg three times daily for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Alcoholic liver disease patients received identical size and shape sugar pill placebo three times daily for 24 weeks.
Study: NCT03191175

Intervention type: OTHER
Intervention: blood sample
Description: 47ml blood (40 ml EDTA whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation and 7 ml for serum).
Study: NCT04716582

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sitting interrupted by light physical activity
Description: Each 30 minutes will be 25 minutes sitting followed by 5 minutes walking that designed as prescribed walking route outside laboratory corridor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sitting with cognitive task
Description: Participants will perform online cognitive task during prolonged sitting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: uninterrupted sitting
Description: Participants will watch documentary during prolonged sitting.
Study: NCT00548314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dermal matrix
Description: 1mm thickness matrix composed of collagen-elastin hydrolosate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dermal matrix
Description: 1mm thickness matrix composed of collagen-elastin hydrolosate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Split skin graft

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VAC therapy (KCI)
Description: VAC therapy for 3-5 days 125mmHg

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VAC therapy (KCI)
Description: VAC therapy for 3-5 days 125mmHg
Study: NCT02681939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tulsi(Ocimum sanctum Linn.) capsules
Study: NCT05091151

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal dexmedetomidine at dose of 2 mcg/kg and 4 mcg/kg
Description: Intranasal dexmedetomidine were given 45 minutes before the MRI procedure through both nostrils using a 1 mL syringe.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal dexmedetomidine at dose of 2 mcg/kg and 4 mcg/kg
Description: Intranasal dexmedetomidine were given 45 minutes before the MRI procedure through both nostrils using a 1 mL syringe.
Study: NCT03317444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC101
Description: Oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral suspension
Study: NCT03251755

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Exercise promotion using Chinese Yoga